Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
81 results about "Gene Expression Inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Agent for suppressing expression of dominant mutant gene
InactiveUS20130197061A1Inhibit expressionMaintain expressionOrganic active ingredientsSugar derivativesWild typeGene
Owner:LSIP
Use of rpn2 gene expression inhibitor
Owner:SUMITOMO DAINIPPON PHARMA CO LTD +3
In vivo inhibition of hepatitis B virus
InactiveUS20060063731A1Reduce the amount requiredReduce drug doseBiocideSpecial deliveryNucleotideMammal
A process is provided to deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similarity to of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of the polynucleotide-based gene expression inhibitor can enhance the efficacy of co-delivered small molecule drugs.
Owner:ROCHE MADISON
Plant pyruvate dehydrogenase kinase gene
InactiveUS6500670B1High activityImprove availabilitySugar derivativesClimate change adaptationBrassicaceaePlanting seed
The present invention relates to the isolation, purification, characterization and use of a mitochondrial pyruvate dehydrogenase kinase (PDHK) gene [SEQ ID NO:1](pYA5; ATCC No 209562) from the Brassicaceae (specifically Arabidopsis thaliana). The invention includes isolated and purified DNA of the stated sequence and relates to methods of regulating fatty acid synthesis, seed oil content, seed size / weight, flowering time, vegetative growth, respiration rate and generation time using the gene and to tissues and plants transformed with the gene. The invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA sequence of SEQ ID NO:1; or a part of SEQ ID NO:1 characterized in that said sequence has been introduced into an antisense or sense orientation, and a method of producing such plants and plant seeds. The invention also relates to substantially homologous DNA sequences from plants encoding proteins with deduced amino acid sequences of 25% or greater identity, and 50% or greater similarity, isolated and / or characterized by known methods using the sequence information of SEQ ID NO:1, and to parts of reduced length that are still able to function as inhibitors of gene expression by use in an anti-sense, co-suppression or other gene silencing technologies.
Owner:NAT RES COUNCIL OF CANADA
Pharmaceutical composition for delayed hypersensitivity
The present invention provides a pharmaceutical composition by a novel action mechanism without serious side effects for delayed hypersensitivity and a screening method of the same. The invention also provides a novel assay method of inhibitors / suppressive agents of PAR-2. The invention relates to a pharmaceutical composition for delayed hypersensitivity containing one or two or more active ingredients selected from the group consisting of inhibitors of PAR-2 and suppressive agents of PAR-2 gene expression and a pharmaceutically acceptable carrier, and to a method for screening active ingredients for pharmaceutical composition for delayed hypersensitivity by contacting a subject substance with cells expressing PAR-2 and by determining expression or activity of PAR-2. The invention also relates to a method for detecting or quantifying actions of the subject substance for PAR-2 using cells expressing PAR-2 in a culture containing inositol.
Owner:KOWA CO LTD
Gene expression inhibitor selective for matrix metalloproteinase-9 gene
Disclosed are: an inhibitor of the expression of matrix metalloproteinase-9 gene; a therapeutic agent for a disease associated with matrix metalloproteinase-9; and a carcinostatic agent. Each of the agents comprises a pyrrole-imidazole polyamide having an N-methylpyrrole unit, an N-methylimidazole unit and a γ-aminobutyric acid unit. The pyrrole-imidazole polyamide can be folded at the site of the γ-aminobutyric acid unit to form a U-shaped conformation in a minor groove of a double-stranded domain comprising a part or the whole of a specific nucleotide sequence (SEQ ID NO:2, SEQ ID NO:4) included in a human matrix metalloproteinase-9 gene promoter and a strand complementary to the part or the whole of the specific nucleotide sequence. In the U-shaped conformation, a Py-Im pair, an Im / Py pair and a Py / Py pair in the pyrrole-imidazole polyamide target a C-G base pair, a G-C base pair, and both of an A-T base pair and a T-A base pair in the minor groove, respectively.
Owner:NIHON UNIVERSITY
FLT3 receptor antagonists for the treatment or the prevention of pain disorders
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
Application of pax4 gene expression inhibitor in the preparation of drugs for inhibiting fibrosis
ActiveCN111214660BClear regulationThe mechanism of action is clearOrganic active ingredientsDigestive systemCardiac fibrosisMedicine
Owner:PEKING UNIV THIRD HOSPITAL
Tgf-Beta Gene Expression Inhibitor
A TGF-β gene expression inhibitor containing a pyrrole-imidazole polyamide having N-methylimidazole unit (hereinafter also referred to as Py), N-methylimidazole unit (hereinafter also referred to as Im) and γ-aminobutyrate unit which can be holded into an U-shaped conformation at the γ-aminobutyrate unit in the minor groove in a double helix region (hereinafter referred to as the target region) containing a complementary chain corresponding to the sequence at the -557 to -536 in the base sequence of a human transforming growth factor β1 (hereinafter also referred to as hTGF-β1) promoter, either as a whole or a part thereof: TAAAGGAGAGCAATTCT-TACAG (SEQ ID NO: 1) wherein a Py / Im pair corresponds to a C-G base pair, an Im / Py pair corresponds to a G-C base pair, and Py / Py pairs correspond respectively to an A-A base pair and a T-A base pair.
Owner:NIHON UNIVERSITY +1
TGF-β gene expression inhibitor
A TGF-β gene expression inhibitor containing a pyrrole-immidazole polyamide comprising an N-methylpyrrole unit (hereinafter also referred to as Py), an N-methylimidazole unit (hereinafter also referred to as Im) and a γ-aminobutyric acid unit which can be folded into an U-shaped conformation at the above-described γ-aminobutyric acid unit site in a minor groove of a double-stranded region (hereinafter referred to as the target region) containing a part or the whole of the following base sequence (SEQ ID NO: 2) corresponding to −450 to −310 of human transforming growth factor β1 (hereinafter also referred to as h TGF-β1) promoter and a strand complementary thereto and in which a Py / Im pair, an Im / Py pair and a PY / Py pair correspond respectively to a C-G base pair, a G-C base pair and an A-T base pair and a T-A base pair.
Owner:NIHON UNIVERSITY +1
Antisense oligonucleotide targeting ENSG00000203930 gene and application of antisense oligonucleotide
ActiveCN113897358AEnhanced inhibitory effectOrganic active ingredientsAntineoplastic agentsGeneticsPharmaceutical drug
The invention relates to an antisense oligonucleotide targeting an ENSG00000203930 gene and application of the antisense oligonucleotide and belongs to the technical field of gene drugs. The invention firstly identifies and discloses an antisense-strand complete sequence of a long-chain non-coding RNA transcript of the ENSG00000203930 gene and also discloses an antisense oligonucleotide sequence which is designed and synthesized on the basis of the antisense-strand complete sequence of the long-chain non-coding RNA transcript of the ENSG00000203930 gene. The invention also discloses application of the antisense oligonucleotide sequence in preparation of an ENSG00000203930 gene expression inhibitor. Research results show that the ASO synthesized or expressed on the basis of a vector can be used for remarkably inhibiting expression of the ENSG00000203930 gene, has an obvious brain metastasis inhibiting effect and has a clinical application prospect.
Owner:STAR PHARM (NANJING) INC
siRNA capable of targeting human tspan8 gene and application of sirna
InactiveCN106467914APrevent proliferationInhibit expressionGenetic material ingredientsFermentationGene Expression InhibitorFhit gene
The invention relates to the fields of biological medicines and gene therapy; the invention provides siRNA or shRNA capable of specifically inhibiting the expression of the TSPAN8 gene, and provides an application of the siRNA or shRNA in preparing a TSPAN8 gene expression inhibitor as well as an application in preparing medicines for preventing or treating gliomas.
Owner:EAST CHINA UNIV OF SCI & TECH
Composition for substituting fructus xanthii to prepare glioma treatment medicine and measuring method
InactiveCN108714147APrevent proliferationInhibition of Biological Behavioral EffectsOrganic active ingredientsComponent separationDicaffeoylquinic acidMedicine
The invention discloses a composition for substituting fructus xanthii to prepare a glioma treatment medicine and a measuring method. The composition composed of neochlorogenic acid, chlorogenic acid,xanthiside, 1,5-dicaffeoylquinic acid and 4,5-dicaffeoylquinic acid basically can substitute an inhibitory effect of the fructus xanthii on mTOR gene expression equivalently, wherein the compositionand the fructus xanthii have equivalent strength; the composition can be used for equivalently substituting the fructus xanthii to prepare an mTOR gene expression inhibitor. Those skilled in the art know that inhibition of the mTOR gene expression can effectively inhibit proliferation of glioma cells (miRNA-99b negatively regulates ability of mTOR for inhibiting invasion of glioma cells. Chinese Pharmacological Bulletin, April 2018, Vol. 34, No. 4); therefore, the composition can be used for equivalent substitution of the fructus xanthii to prepare the glioma treatment medicine.
Owner:杨真慧
Methods for the treatment and diagnosis of bone mineral density related diseases
ActiveUS20150104437A1Difficult to solveAvoid side effectsBiocideOrganic active ingredientsGhosal hematodiaphyseal dysplasiaDisease
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Small cell lung cancer therapeutic agent containing oligonucleotide
Disclosed is an oligonucleotide, or a pharmacologically acceptable salt thereof, that contains at least one prescribed nucleoside structure, is capable of binding with a human nSR100 gene, and has activity to suppress the expression of the human nSR100 gene. The length of this oligonucleotide is 12-20 bases, and the oligonucleotide is complementary to a prescribed target region. Also disclosed isan nSR100-gene-expression-suppressing agent and a cancer therapeutic agent that contain the oligonucleotide or a pharmacologically acceptable salt thereof. This cancer therapeutic agent can be used inthe treatment of small cell lung cancer, prostate cancer, or breast cancer.
Owner:OSAKA UNIV +2
Gene expression inhibitors
ActiveUS20200270305A1Reduce transcriptionReduce translationAntibacterial agentsPolypeptide with localisation/targeting motifGene Expression InhibitorAmino acid
The present invention relates to a peptide comprising or consisting of an amino acid sequence according to formula (I) X1-X2-X3-X4-X5-(A)m-X6-X7-(X8)n-C (I), wherein X1 is C or S, X2 is L or A, X3 is A, V or L, X4 is F or Y, X5 is Y or F, X6 is C or R, X7 is F or L, X8 is W or A and m and n are independently 0 or 1 or a variant thereof.
Owner:PIVARIS BIOSCIENCE GMBH
Application of Htra2 gene expression inhibitor in prevention of acquired sensorineural deafness
ActiveCN113181376APrevention of Ototoxic DeafnessOrganic active ingredientsSenses disorderAminosugarGene Expression Inhibitor
The invention discloses an application of an Htra2 gene expression inhibitor in prevention of acquired sensorineural deafness. The Htra2 gene expression inhibitor is used for preventing ototoxic deafness caused by aminoglycoside antibiotics. The invention also provides a CRISPR / Cas9 gene editing system for preventing the acquired sensorineural deafness, and the CRISPR / Cas9 gene editing system is used for targeting and knocking out the Htra2 gene. The invention proves that the AAV-CRISPR / Cas9-Htra2 gene editing system inner ear microinjection can be used for safely and effectively preventing the ototoxic deafness caused by the aminoglycoside antibiotics.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
Composition for promoting chondrocyte differentiation or treating cartilage diseases, containing KLF10 expression inhibitor, and method for promoting cartilage differentiation by using same
ActiveUS20170016003A1Good effectInhibiting cartilage hypertrophyMicrobiological testing/measurementGenetically modified cellsEccentric hypertrophyDisease
The present invention relates to a Krueppel-like factor 10 (KLF10) gene expression inhibitor promoting cartilage differentiation, and more specifically, to: a composition for promoting chondrocyte differentiation or treating cartilage diseases, containing a KLF10 gene expression inhibitor promoting cartilage differentiation and inhibiting the hypertrophy and dedifferentiation of chondrocytes; a cell therapeutic agent containing the composition; a method for promoting cartilage differentiation in bone marrow stem cells, comprising a step of expressing the composition in bone marrow stem cells; and a method for screening a chondrocyte differentiation promoter or a chondrocyte therapeutic agent. The present invention first examined the generation inhibition mechanism of indian hedgehog (IHH) protein of which the molecular biological mechanism has not yet been clearly examined, and ascertained that chondrocyte differentiation is promoted and chondrocyte hypertrophy is inhibited when chondrocyte differentiation is induced by expressing the KLF10 expression inhibitor in bone marrow stem cells. Therefore, the present invention has an advantage of enabling the use of bone marrow stem cells, which express a KLF10 expression inhibitor, as a chondrocyte therapeutic agent.
Owner:DONGGUK UNIV IND ACADEMIC COOPERATION FOUND
Composition for replacing radix bupleuri to prepare glioma treatment medicine and determination method of composition
InactiveCN108721312APrevent proliferationInhibition of Biological Behavioral EffectsOrganic active ingredientsComponent separationPharmacometricsPharmaceutical drug
The invention discloses composition for replacing radix bupleuri to prepare a glioma treatment medicine and a determination method of the composition. The composition consisting of saikosaponins F, G,C, A and D can basically equivalently replace the inhibition effect of the radix bupleuri to expression of an mTOR gene and has the same intensity with the radix bupleuri. The composition can equivalently replace the radix bupleuri to prepare an mTOR gene expression inhibitor. The skilled in the art know that inhibition of the expression of the mTOR gene can effectively inhibit proliferation of glioma cells (miRNA-99b negatively regulates the invasion ability of mTOR in inhibiting glioma cells, China Pharmacology General, volume 34, number 4, in 4, 2018), so that the composition can be used for equivalently replace the radix bupleuri to prepare the glioma treatment medicine.
Owner:杨真慧
Method for treating and prognosing cancer
ActiveUS20200282011A1Improved prognosisPoor prognosisOrganic active ingredientsCompound screeningCancer preventionChemical compound
The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A / ISGF3γ in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value.The invention also relates a compound which is a DNMT3A / ISGF3γ antagonist or a compound which is a DNMT3A / ISGF3γ gene expression inhibitor for use in the treatment and prevention of cancer.
Owner:NANTES UNIVERSITÉ +2
Method for treating and prognosing cancer
ActiveUS10697965B2Blocks the action of these proteinsBiological activity is prevented and reducedCompound screeningApoptosis detectionCancer preventionChemical compound
The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A / ISGF3γ in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A / ISGF3γ antagonist or a compound which is a DNMT3A / ISGF3γ gene expression inhibitor for use in the treatment and prevention of cancer.
Owner:UNIV DE NANTES +2
Composition for preparing medicines for treating cervical cancer by replacing Paris polyphylla and testing method for composition
ActiveCN108635363APrevent proliferationInhibition of Proliferative EffectsOrganic active ingredientsComponent separationGynecologyIsrapafant
The invention discloses a composition for preparing medicines for treating cervical cancer by replacing Paris polyphylla and a testing method for the composition. The composition composed of parissaponin VII, pennogenin-3-O-alpha-L-Rha(1-2)[alpha-L-Rha(1-4)]-beta-D-Glc, parissaponin H, parissaponin II and gracillin basically can equivalently replace the inhibiting effect of Paris polyphylla for the expression of the p62 gene, and the intensities of the two are equivalent. The composition can be used for preparing inhibitors for the expression of the p62 gene by equivalently replacing Paris polyphylla. As known to those skilled in the art, the proliferation of the cervical cancer cells can be effectively inhibited by inhibiting the expression of the p62 gene (The influences on the cervicalcancer HeLa cell proliferation by inhibiting on the expression of the p62 gene through RNA interference, the Journal of Bengbu Medical College, Vol.43, No.1 (2018.1), and therefore, the composition can be used for preparing the medicines for treating cervical cancer by equivalently replacing Paris polyphylla.
Owner:深圳深创生物技术有限公司
Application of POU2F1 gene expression inhibitor in preparation of drugs treating tissue fibrosis diseases
ActiveCN111001003APromotes transdifferentiationOrganic active ingredientsMicrobiological testing/measurementCardiac fibrosisDisease
The invention provides a new application of POU2F1 (POU domain class 2transcription factor 1) as a new important target for treating fibrosis. Specifically, the invention provides a treatment method,the expression of the transcription factor POU2F1 is interfered through small interfering RNA so as to block the inhibiting effect of the transcription factor POU2F1 on downstream genes, so that multiple fibrosis inhibiting factors on the downstream can play a role, thus inhibiting cardiac fibrosis.
Owner:PEKING UNIV THIRD HOSPITAL
Application of PAX4 gene expression inhibitor to preparation of medicines for restraining fibrosis
ActiveCN111214660AClear regulationThe mechanism of action is clearOrganic active ingredientsDigestive systemPAX4Fibrosis
The invention discloses an application of a PAX4 gene expression inhibitor to preparation of medicines for restraining fibrosis. The experiment confirms that the restraining effects on downstream genes can be blocked through interference of the expression of transcription factors PAX4 by small-interference RNA, and a plurality of downstream fibrosis restraining factors can exert functions; the expression of the PAX4 is reduced by the small-interference RNA, at the same time, the expression level of fibrosis enhancing factors is also reduced, and fibrosis promoting effects can be restrained, sothat the generation of heart fibrosis is restrained; and therefore, the PAX4 is a potential bran-new important target point in the heart, for treating the heart fibrosis so as to prevent heart failure.
Owner:PEKING UNIV THIRD HOSPITAL
Novel pi polyamide
ActiveUS20160032057A1Development of safe and stableEffective preventionOrganic chemistryMicrobiological testing/measurementProstate cancerPolyamide
To provide a safe and stable medicine useful for prevention and treatment of prostate cancer.A novel PI polyamide is acquired that recognizes and binds to a specific base sequence of an Oct1 gene binding sequence present in a transcriptional regulatory region (AR response region) of an ACSL3 gene and regulating the transcription activity of AR. This leads to the provision of an ACSL3 gene expression inhibitor and a preventive and / or therapeutic agent of prostate cancer containing the PI polyamide as an active ingredient.
Owner:NIHON UNIVERSITY
Bupleurum bicaule substituting composition for preparation of prostate cancer therapeutic drugs and determination method thereof
InactiveCN108434168APrevent proliferationInhibition of Biological Behavioral EffectsOrganic active ingredientsComponent separationCancer preventionProstate cancer cell
The invention discloses a bupleurum bicaule substituting composition for preparation of prostate cancer therapeutic drugs and a determination method thereof. The composition composed of bupleurum prosapogenin F, bupleurum prosapogenin I, bupleurum prosapogenin C, bupleurum prosapogenin A and bupleurum prosapogenin D basically can substitute the inhibitory effect of bupleurum bicaule on AMPK gene expression, and the two have equivalent intensity. The composition can be used for equivalent substitution of bupleurum bicaule to prepare AMPK gene expression inhibitors. The technical staff of the technical field are aware that inhibition of the AMPK gene expression can effectively inhibit the proliferation of prostate cancer cells (influence of RNA interference silencing of AMPK on the biological behaviors of prostate cancer cells, Chinese Journal of Cancer Prevention and Treatment, Volume 25, Issue 2, Jan. 2018). Therefore, the composition can be used for equivalent substitution of bupleurum bicaule to prepare prostate cancer therapeutic drugs.
Owner:杨真慧
Method For Treating Breast Cancer By Targeting Breast Cancer Stem Cell
ActiveUS20160060634A1Growth inhibitionOxidoreductasesFermentationLymphatic SpreadBULK ACTIVE INGREDIENT
The present invention relates to a composition for inhibiting growth of cancer stem cells, which includes an EXT1, LDHB, CD109, EFEMP2, RASIP1 or SERPINE1 gene expression inhibitor as an active ingredient, and a method of treating cancer using the same. The composition has targeted therapeutic activities against cancer stem cells important for resistance, metastasis and recurrence of breast cancer, and thus can be useful in fundamentally treating, preventing or alleviating cancer such as breast cancer by directly inhibiting expression of EXT1, LDHB, CD109, EFEMP2, RASIP1 or SERPINE1 which are very important for growth of the cancer stem cells.
Owner:KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND
New method for treating and prognosing cancer
ActiveUS20180238885A1Short survival timeIncreased cell deathCompound screeningApoptosis detectionCancer preventionGood prognosis
The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A / ISGF3γ in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A / ISGF3γ antagonist or a compound which is a DNMT3A / ISGF3γ gene expression inhibitor for use in the treatment and prevention of cancer.
Owner:UNIV DE NANTES +2
Tgf-ß Gene Expression Inhibitor
A TGF-β gene expression inhibitor containing a pyrrole-immidazole polyamide comprising an N-methylpyrrole unit (hereinafter also referred to as Py), an N-methylimidazole unit (hereinafter also referred to as Im) and a γ-aminobutyric acid unit which can be folded into an U-shaped conformation at the above-described γ-aminobutyric acid unit site in a minor groove of a double-stranded region (hereinafter referred to as the target region) containing a part or the whole of the following base sequence (SEQ ID NO: 2) corresponding to −450 to −310 of human transforming growth factor β1 (hereinafter also referred to as h TGF-β1) promoter and a strand complementary thereto and in which a Py / Im pair, an Im / Py pair and a PY / Py pair correspond respectively to a C-G base pair, a G-C base pair and an A-T base pair and a T-A base pair.
Owner:NIHON UNIVERSITY +1
Composition for Treatment or Metastasis Suppression of Cancers Which Includes P34 Expression Inhibitor or Activity Inhibitor as Active Ingredient
ActiveUS20160040168A1Improve stabilityAffect poly-ubiquitinationOrganic active ingredientsSugar derivativesAbnormal tissue growthCancer cell
The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of PTEN and accordingly nuclear localization of PTEN is induced, as a result, an Akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express PTEN and NEDD4-1. Consequently, the p34 gene expression inhibitor or p34 protein activity inhibitor according to the present invention can be effectively used as a treatment agent or a metastasis suppression agent for cancers.
Owner:THE ASAN FOUND +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com